SOURCE: Market Pulse

December 17, 2009 08:30 ET

Market Pulse Breaking News Alert for Thursday, December 17, 2009: RMCP -- CT Scan Cancer Revelation Makes Need for RevMed's MRI Technology Critical and RevMed Partners in One of the World's Largest Syringe Markets!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Market Pulse

ATLANTA, GA--(Marketwire - December 17, 2009) - Market Pulse News Alert for this AM, Stocks to Watch are: Revolutions Medical Corporation (OTCBB: RMCP), Delta Petroleum Corp. (NASDAQ: DPTR), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN) and NVIDIA Corporation (NASDAQ: NVDA).

Investors need to be watching Revolutions Medical Corporation (OTCBB: RMCP) this AM! Revolutions Medical Corporation (RevMed) is engaged in the design, development, commercialization and acquisition of new products and tools to make healthcare safer and less expensive. RevMed's products include safety-engineered medical devices (SEMDs) and the flagship RevVac safety syringe (FDA Approved), safety blood drawing devices, and safety IV catheters. The products use a proprietary patented technology in which a vacuum causes the needle to retract into the barrel of the syringe or device after an injection is administered or blood is drawn. RevMed owns the patents to manufacture the disposable retractable syringe and phlebotomy device. The world market for SEMDs is projected to exceed $2 billion this year and is forecasted to maintain a 20% annual growth rate in the near term. RevMed also offers RevColor, RevDisplay and Rev3D, software solutions and proprietary tools that are compatible with standard MRIs and standard PACS. The software includes sorting of images, color, 3D, and automatic segmentation of images. These tools will enhance the physician's diagnostic confidence in an industry that is growing at 10% - 15% (more than 25 million procedures) per year with a worldwide market potential for these tools that exceeds $3.5 billion. The company is continually looking for new and improved technology through internal product development and acquisition. The company's future growth will be powered by new product line introductions, and the material expansion of existing successful lines. RevMed's Breast Biopsy System (BBS), stereotactic (minimally invasive) image-based localization technology, is one of those product lines pursuing the $9.5 billion breast screening industry. RevMed's Breast Biopsy System, the MRI enhancement software and the SEMDs will be launching in the next 18 months. All three markets are immediately addressable and total more than $14 billion. RevMed recently introduced its proprietary suite of MRI software products at the Radiology Society of North America annual meeting with great success. Radiologists and universities world-wide received presentations at the RMCP booth. A number of these contacts could play an important role in the company's ongoing efforts to clinically validate specific applications of its MRI tools prior to the 2010 commercial launch. Never has health care been a hotter issue, and the focus of the conversation is on increased safety at dramatically reduced cost. Revolutions Medical has the formula for success, and one that has them immediately positioned for a high growth future. With 3 recurring revenue business lines with blended gross margins projected to exceed 50% and anticipated profitability in its first full year of operations, Revolutions Medical Corporation is poised to become a significant player in the healthcare and medical devices industry! RMCP has had several excellent press releases out lately and one again before today's opening bell announcing that recent mass media reports that CT scans cause cancer could rapidly elevate MRI as the technology of choice for musculoskeletal scans and more! The company also announced yesterday that it has forged a distribution partnership for the RevVac safety syringe in South America, one of the world's largest syringe markets! This could be great news for investors!

Revolutions Medical Corporation (OTCBB: RMCP), producers of the RevVac safety syringe, RevColor, RevDisplay and Rev3D MRI Technology, announced today that recent mass media reports that CT scans cause cancer could rapidly elevate MRI as the technology of choice for musculoskeletal scans and more. A resulting spike in the number of MRI scans would not be met by an equal increase in the number of radiologists, making the need to arm the existing ranks with enhanced diagnostic tools a critical one.

According to the Archives of Internal Medicine (, radiation from CT scans done in 2007 alone will cause 29,000 cancers (including 2,000 excess breast cancer cases) and kill nearly 15,000 Americans. Read the following major media outlet features:


Wall Street Journal:


"This is nothing short of a bombshell announcement for the MRI industry," stated Revolutions Medical CTO Richard Theriault. "MRI has long been a potential replacement for CT scans across a variety of applications, but CT has been the physicians' choice as the less expensive of the two options. With the very real dangers of CT now exposed, patient safety will likely trump cost concerns. Moreover, as insurance companies evaluate the financial impact of a cancer case vs. a moderately more expensive scan, the math may drive a mandated move to MRI.

"What does this mean for RevMed? The number of radiologists has remained constant in recent years, even as the Baby Boomers age and MRI scan counts are steadily climbing. We are nearing an alarming tipping point where there will be more scans than professionals to read them; add to that a potential immediate and substantial shift from CT to MRI and the possibility for widespread misdiagnoses is a real one. Radiologists need a tool that makes the reading of scans more efficient and intuitive, and increases diagnostic confidence even at a faster pace. The RevMed MRI Technology (RevColor, RevDisplay and Rev3D) could provide exactly that solution. With our ability to convert standard grayscale scans to segmented, three-dimensional, color images we can help radiologists arrive at the correct diagnosis much more quickly, and at less risk to the patient."

About Revolutions Medical Corporation (

RevMed's products include the RevVac safety syringe (FDA approved), safety blood drawing device and safety IV catheter. RevMed also provides RevColor, RevDisplay and Rev3D -- software solutions and proprietary tools that are compatible with standard MRIs and standard PACS. The software suite's functionality includes sorting of images, color, 3D and automatic segmentation of images.

Investor Resource Center

Fact Sheet:

CEO Ron Wheet Audio Interview:

RevVac Demo Video:

Stocks in the news and acting well as of late include: Delta Petroleum Corp. (NASDAQ: DPTR), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN) and NVIDIA Corporation (NASDAQ: NVDA).

Information contained herein is the opinion of ("MP") and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.

MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.

You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated twenty five thousand restricted shares of Revolutions Medical Corporation by the company. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services. and Market Pulse Breaking News Alert are owned by Market Pulse LLC.

Contact Information